Kevin Girard received a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute in 1994. He later earned an M.S. and Ph.D. from the University of Pennsylvania in 1999. Dr. Girard began an industrial career as a chemical engineer with Bristol-Myers Squibb (BMS), where he studied the filtration and drying of active pharmaceutical ingredients (API’s). This assignment put Kevin at the interface between API and drug and allowed him to be one of the key players in the early adoption of Process Analytical Technology (PAT) at BMS. In 2006, Dr. Girard joined Pfizer, where he has spent the last 19 years in the Pfizer Crystallization Technology Lab (CTL) and Flexible API Supply Technology (FAST) groups. Kevin has lead the development and implementation of new and emerging crystallization technology and has applied these tools to develop crystallization processes for over 31 different medicines that are on the market or in development. To date, Kevin’s processes have been used in the manufacture of Reyataz™, Tequin™, Baraclude™, Vyndaquel™, Bosulif™, Vizimpro™, and Abrocitinib™. Dr. Girard has over 30 peer-reviewed publications and four international patents. When he is not busy crystallizing the next wave of therapies, Kevin enjoys aviation (instrument rated pilot), golf, kiteboarding, coaching/watching/playing soccer, and spending time with his three children in SE CT.